Introduction: Prostate cancer is the second most common type of cancer in men worldwide, surpassed only by lung cancer. The risk of prostate cancer is related to age, ethnicity, family history, PSA level, and findings on digital rectal examination. The main therapeutic approaches are surgical procedures (prostatectomies), radiotherapy, and hormone therapies, which can be applied alone or in combination, in addition to active surveillance. The choice of treatment type will depend on the stage of the disease and the risk of metastasis. Objectives: This study aims to analyze the incidence of prostate cancer in Brazilian regions between 2021 and 2025, as well as the epidemiological profile of this disease. Methods: This is a retrospective, observational, and descriptive study, quantitative in nature, based on secondary data extracted from DATASUS. Prostate cancer cases between the years 2021 and 2025 were analyzed, considering the following variables: region of residence, age group, and therapeutic management. The data were organized in spreadsheets using Microsoft Excel software. Results: A total of 162,899 cases of prostate cancer were recorded during the study period. The region with the highest incidence was the Southeast (0.19), followed by the South (0.17) and Northeast (0.14) regions; the Central-West (0.09) and North (0.07) regions had the lowest incidences. Regarding the age group, a proportional increase in cases was observed with advancing age, with 76% of cases occurring between 60 and 79 years old, peaking in diagnoses between 65 and 69 years old (22.39%). Regarding therapeutic management, underreporting was identified in 25.72% of cases, which lacked information on this variable. Despite this, it was found that the most used treatment was chemotherapy (46.42%), followed by surgery (16.19%) and radiotherapy (11.28%). Conclusion: The incidence of prostate cancer in Brazil shows significant regional heterogeneity, possibly influenced by unequal access to health services and diagnostic methods. Regarding the age group, it became evident that the risk increases progressively with age, with the subgroup between 65 and 69 years old being at the highest risk. Nevertheless, the 50 to 60 age range is crucial for early detection, justifying specific screening strategies. Furthermore, data on therapeutic management suggest underreporting at the national level, which hinders obtaining a reliable sample of the Brazilian reality. Moreover, DATASUS data do not include therapeutic forms such as hormone blockade and active surveillance, which may lead to an incomplete analysis of this variable. Despite these limitations, it is evident that treatment forms vary according to the patient's age and disease stage, reinforcing the need for individualization and adequate access to therapy. These findings highlight the importance of public policies that reduce regional inequalities in access to diagnosis and treatment of prostate cancer in Brazil.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
